Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 6:6:46.
doi: 10.3389/fped.2018.00046. eCollection 2018.

Cefepime Efficacy and Safety in Children: A Systematic Review and Meta-analysis

Saber Jan  1   2 , Braveen Ragunanthan  3 , Sandra R DiBrito  4 , Omolabake Alabi  5 , Maria Gutierrez  6
Affiliations

Cefepime Efficacy and Safety in Children: A Systematic Review and Meta-analysis

Saber Jan et al. Front Pediatr. .

Abstract

Background: Cefepime is a fourth-generation cephalosporin antibiotic used to treat a variety of infections. The US Food and Drug Administration approved its use in certain types of infections among pediatric patients, and yet there have been mixed data about its efficacy and safety in this population.

Objective: The objective of this review is to compare efficacy and all-cause mortality of cefepime to other clinically indicated antibiotics among children.

Methods: We conducted a systematic search of MEDLINE, EMBASE, CENTRAL, LILACS, and clinicaltrials.gov databases through February 8, 2016. We included randomized controlled trials comparing cefepime to other clinical antibiotics, placebo, or no treatment in children aged 0-19 years in the inpatient setting with clinical signs of infection. The primary outcome of interest was all-cause mortality. The secondary outcomes were success rate, treatment failure, and incidence of adverse events. Study quality was assessed using the Cochrane Risk of Bias Assessment Tool.

Results: Seventeen studies met the inclusion criteria. There was a total of 1,285 participants included, 624 participants in the cefepime arm and 661 in the comparison arm. A random effects meta-analysis for all-cause mortality showed no difference in rates of mortality between cefepime and comparator antibiotics with a mortality risk ratio of 0.88 (95% CI: 0.71-1.08). For the secondary outcomes of success rate and treatment failure, a random effects model meta-analysis conducted of the studies showed no difference in rate between cefepime and comparator antibiotics with an overall risk ratio of 0.98 (95% CI: 0.92-1.05) and 1.04 (95% CI: 0.91-1.19), respectively. Adverse events were not statistically assessed given widespread heterogeneity. Overall, the studies had unclear risk of bias and were limited by high heterogeneity and methodological flaws.

Conclusion: The efficacy and safety of cefepime in pediatric patients remain unclear despite the inclusion of newer trials since the last index systematic review conducted a decade ago.

Keywords: antibiotic; cefepime; cephalosporin; children; efficacy; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection flow chart.
Figure 2
Figure 2
Risk of bias summary of the included studies.
Figure 3
Figure 3
Risk of bias graph of the included studies.
Figure 4
Figure 4
All-cause mortality for cefepime versus comparator.
Figure 5
Figure 5
Success rate for cefepime versus comparator.
Figure 6
Figure 6
Treatment failure for cefepime versus comparator.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. AHFS Consumer Medication Information. Cefepime Injection. Bethesda, MD: American Society of Health-System Pharmacists, Inc. (2016). Available from: https://www.nlm.nih.gov/medlineplus/druginfo/meds/a698021.html
    1. Paul M, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials: authors’ response [2]. J Antimicrob Chemother (2006) 58(2):479–80.10.1093/jac/dki448 - DOI - PubMed
    1. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis (2007) 7(5):338–48.10.1016/S1473-3099(07)70109-3 - DOI - PubMed
    1. Food and Drug Administration (FDA). Early Communication About an Ongoing Safety Review of Cefepime (Marketed as Maxipime). (2007). Available from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforP...
    1. Food and Drug Administration (FDA). Cefepime (Marketed as Maxipime) Safety Review: An Update. (2009). Available from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforP...

LinkOut - more resources